Scarica l'app Stockscreener
109.99
4.69%
-5.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$115.61
Aprire:
$114.25
Volume 24 ore:
501.69K
Relative Volume:
0.14
Capitalizzazione di mercato:
$23.84B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-19.15
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
-1.21%
1M Prestazione:
+12.61%
6M Prestazione:
-32.70%
1 anno Prestazione:
+12.23%
Intervallo 1D:
$109.72
$115.55
Intervallo di 1 settimana:
$109.72
$119.54
Portata 52W:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
109.98 | 25.06B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
476.75 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
658.03 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.05 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.25 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
280.23 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM - TradingView
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
MSN Money - MSN
What's Driving Insmed's Recent Volatility - Kavout | AI
Enterprise value to revenue forward of Insmed Incorporated – BMV:INSM - TradingView
Insmed CEO William Lewis sells over $1.25m in company stock By Investing.com - Investing.com India
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing - Moomoo
Insmed CEO William Lewis sells over $1.25m in company stock - Investing.com
Form 4 Insmed Inc For: 10 July By Investing.com - Investing.com South Africa
INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares - Stock Titan
INSM Reiterated by Guggenheim -- Price Target Maintained at $207 - GuruFocus
Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Form 144 INSMED INC For: 9 July By Investing.com - Investing.com India
INSM (NASDAQ: INSM) affiliate William Lewis reports multiple share sales - Stock Titan
INSM Technical Analysis & Stock Price Forecast - Intellectia AI
Insmed CMO Martina Flammer sells $1.35m in stock - Investing.com
Insmed (NASDAQ:INSM) Drug Launch Fuels Healthcare Market Buzz - Kalkine Media
Form 4 Insmed Inc For: 8 July By Investing.com - Investing.com South Africa
Insmed CMO Martina Flammer sells $1.35m in stock By Investing.com - Investing.com South Africa
Insmed (INSM) CMO sells 12,302 shares after option exercises - Stock Titan
Morgan Stanley Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Non-Cystic Fibrosis Bronchiectasis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farma - Barchart.com
Martina Flammer reports multiple INSM (NASDAQ: INSM) share dispositions in Form 144 - Stock Titan
INSMInsmed Inc Options - Finviz
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead - Investing.com
Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM) - Yahoo Finance
Analysts Expect Breakeven For Insmed Incorporated (NASDAQ:INSM) Before Long - Moomoo
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS:INSM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 2500 Index - marketscreener.com
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM) - Yahoo Finance
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell Midcap Value Benchmark - marketscreener.com
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing - marketscreener.com
INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan - Stock Titan
Price to earnings forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Form 144 INSMED INC For: 25 June - Investing.com UK
Form 144 INSMED INC For: 25 June By Investing.com - Investing.com Nigeria
Insmed Incorporated Actuals & Estimates (NASDAQ:INSM) - TradingView
Insmed Incorporated Actuals & Estimates (BX:IM8N) - TradingView
William Lewis files Form 144 — Insmed (NASDAQ: INSM) reports recent share dispositions - Stock Titan
Insmed | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Enterprise value to EBITDA forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Jul 09 '26 |
Sale |
117.40 |
10,699 |
1,256,084 |
259,058 |
0.47%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):